Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 jan 2007 - 08:03
Statutaire naam
Crucell N.V.
Titel
Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation
Bericht
Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation
Sittard/Leiden, The Netherlands, 11 January 2007 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with the Taiwan-based AbGenomics Corporation.
AbGenomics Corporation intends to use the PER.C6® cell line for its research, development and early clinical studies of monoclonal antibodies.
"The unique characteristics of the PER.C6® technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology’s robustness undoubtedly makes our choice for PER.C6® highly imperative,” said Shih-Yao Lin, PhD, AbGenomics Corporation’s President.
Under the terms of this agreement, AbGenomics Corporation will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed.
Datum laatste update: 11 januari 2026